Sanofi: beats consensus in Q3
(CercleFinance.com) - Sanofi has reported Q3 2019 net income that is up 4.
3% at 2,399 million euros (+0.2% at constant exchange rates, meaning flat EPS from operations of 1.92 euro at constant exchange rates), hence beating the consensus by 20 cents.
Supported by Sanofi Genzyme and vaccines, the French healthcare giant's sales amounted to 9,499 million euros, up 1.1% as reported, but down 1.1%. at constant exchange rates and up 0.5% like-for-like.
Sanofi confirms its EPS outlook for businesses in 2019, estimating growth of around 5% at constant exchange rates, barring any unexpected major adverse events. FX factors are expected to have a favourable impact of around +3%, applying average exchange rates for October.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
3% at 2,399 million euros (+0.2% at constant exchange rates, meaning flat EPS from operations of 1.92 euro at constant exchange rates), hence beating the consensus by 20 cents.
Supported by Sanofi Genzyme and vaccines, the French healthcare giant's sales amounted to 9,499 million euros, up 1.1% as reported, but down 1.1%. at constant exchange rates and up 0.5% like-for-like.
Sanofi confirms its EPS outlook for businesses in 2019, estimating growth of around 5% at constant exchange rates, barring any unexpected major adverse events. FX factors are expected to have a favourable impact of around +3%, applying average exchange rates for October.
Copyright (c) 2019 CercleFinance.com. All rights reserved.